Jane Street
TRVI icon

Jane Street’s Trevi Therapeutics TRVI Stock Holding History

Jane Street’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,995
Closed -$515K – 13009
2025
Q4 		$576K Buy
+45,995
New +$532K ﹤0.01% 7375
2024
Q4 		– Sell
-32,929
Closed -$110K – 10612
2024
Q3 		$110K Sell
32,929
-33,439
-50% -$99.4K ﹤0.01% 8961
2024
Q2 		$198K Buy
66,368
+49,274
+288% +$137K ﹤0.01% 8395
2024
Q1 		$59K Sell
17,094
-48,859
-74% -$109K ﹤0.01% 8704
2023
Q4 		$88.4K Buy
65,953
+41,353
+168% +$62.6K ﹤0.01% 8628
2023
Q3 		$53.6K Buy
+24,600
New +$55.6K ﹤0.01% 8132

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Jane Street's TRVI Position: Q1 2026 in Review

Jane Street sold out of Trevi Therapeutics (TRVI) in Q1 2026, closing a stake of 45,995 shares — an estimated $515K sold.

Jane Street first reported a position in TRVI in Q3 2023 and held it in 6 quarters. The position peaked at $576K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Jane Street reported no remaining Trevi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 45,995 Trevi Therapeutics shares in Q1 2026, an estimated $515K.
  • Jane Street first reported a position in Trevi Therapeutics in Q3 2023 and held it in 6 quarters.
  • Jane Street's Trevi Therapeutics position peaked at $576K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.